EFFECT OF COVID-19 ON CARDIOVASCULAR DISEASES ACCORDING TO LITERATURE
Abstract
The article is devoted to a review of data on the prevalence and impact of cardiovascular diseases on the course and outcomes of the new coronavirus infection COVID-19. The review examines the relationship between COVID-19 and the functioning of the renin-angiotensin-aldosterone system, the pathophysiological mechanisms of their mutual influence. The analysis of the latest literature data on the safety of taking angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers is presented. The causes and pathophysiological mechanisms of the development of acute myocardial damage in COVID-19 are discussed. The issue of organizing rehabilitation assistance for patients who have undergone COVID-19 is being considered. The main components and features of the COVID-19 rehabilitation program are presented.
References
World Health Organization. Coronavirus disease 2019 (COVID-19) situation report – 48. Available at: https://www.who.int/docs/defaultsource/coronaviruse/situationreports/20200308sitrep48covid19.pdf?sfvrsn=16f7ccef_4 [Accessed: March 9, 2020].
Wang D., Hu B., Hu C. et al. Clinical characteristics of 138hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061– 1069. DOI: 10.1001/jama.2020.1585.
Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46 (5): 846–848. DOI: 10.1007/s00134-020-05991-x.
Guan W.J., Liang W.H., Zhao Y. et al. Comorbidity and itsimpact on 1590 patients with Covid-19 in China: A Nationwide analysis. Eur. Respir. J. 2020; 55 (5): 2000547.DOI: 10.1183/13993003.00547-2020.
Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020; 323 (18): 1775–1776. DOI: 10.1001/ jama.2020.4683.
Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140- 6736(20)30183-5.
Guzik T., Mohiddin S.A., Dimarco A. et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc. Res. 2020; 116 (10): 1666–1687. DOI: 10.1093/cvr/cvaa106.
Guan W.J., Ni Z.Y., Hu Y. et al. China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020; 382 (18): 1708–1720. DOI: 10.1056/NEJMoa2002032.
Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult in patients with COVID19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.
Kreutz R., Algharably E.A., Azizi M. et al. Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc. Res. 2020; 116 (10): 1688–1699. DOI: 10.1093/cvr/cvaa097.
Zhang H., Penninger J.M., Li Y. et al. Angiotensin- converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46 (4): 586–590. DOI: 10.1007/ s00134-020-05985-9.
Siedlinski M., Jozefczuk E., Xu X. et al. White blood cells and blood pressure: a mendelian randomization study. Circulation. 2020; 141 (16): 1307–1317. DOI: 10.1161/CIRCULATIONAHA.119.045102.
Danser A.H.J., Epstein M., Batlle D. Renin–angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin–angiotensin system blockers. Hypertension. 2020; 75 (6): 1382–1385. DOI: 10.1161/HYPERTENSIONAHA.120.15082.
Nicin L., Abplanalp W.T., Mellentin H. et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur. Heart J. 2020; 41 (19): 1804–1806. DOI: 10.1093/eurheartj/ehaa311.
Li J., Wang X., Chen J. et al. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020; 5 (7): 825–830. DOI: 10.1001/jamacardio.2020.1624.
Mancia G., Rea F., Ludergnani M. et al. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N. Engl. J. Med. 2020; 382 (25): 2431–2440. DOI: 10.1056/NEJMoa2006923.
Gao C., Cai Y., Zhang K. et al. Association of hypertension and antihypertensive treatment with COVID19 mortality: a retrospective observational study. Eur. Heart J. 2020; 41 (22): 2058–2066. DOI: 10.1093/eurheartj/ehaa433.
ESC European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACEinhibitors and angiotensin receptor blockers. 2020, Mar. 13. Available at: https://www.escardio.org/Councils/CouncilonHypertension(CHT)/News/positionstatementoftheesccouncilonhypertensiononaceinhibitorsandang
American Colledge of Cardiology. COVID-19 clinical guidance for the cardiovascular care team. Available at: https://www.acc.org/~/media/665AFA1E710B4B3293138D14BE8D1213.pdf [Accessed: March 12, 2020].
Hendren N.S., Drazner M.H., Bozkurt B., Cooper L.T. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020; 141 (23): 1903– 1914. DOI: 10.1161/CIRCULATIONAHA.120.047349.
Cooper L.T.Jr. Myocarditis. N. Engl. J. Med. 2009; 360 (15): 1526–1538. DOI: 10.1056/NEJMra0800028.
Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab. Syndr. 2020; 14 (3): 247–250. DOI: 10.1016/j.dsx.2020.03.013
Shi S., Qin M., Shen B. et al. Association of cardiac injury with mortality in hospitalized patients with COVID19 in Wuhan, China. JAMA Cardiol. 2020; 5 (7): 802 810. DOI: 10.1001/jamacardio.2020.0950.
Arentz M., Yim E., Klaff L. et al. Characteristics and out- comes of 21 critically ill patients with COVID19 in Washington State. JAMA. 2020; 323 (16): 1612–1614. DOI: 10.1001/jama.2020.4326.
Li B., Yang J., Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020; 109 (5): 531–538. DOI: 10.1007/s00392-020-01626-9.
Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5 (7): 811–818. DOI: 10.1001/jamacardio.2020.1017.
Shi S., Qin M., Cai Y. et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur. Heart J. 2020; 41 (22): 2070–2079. DOI: 10.1093/eurheartj/ehaa408.
Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID 19 in Italy. JAMA. 2020; 323 (18): 1775–1776. DOI: 10.1001/jama.2020.4683.
ESC European Society of Cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. Available at: https://www.escardio.org/Education/COVID19andCardiology/ESCCOVID19Guidance
Views:
161
Downloads:
122
Copyright (c) 2021 The authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
